VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO GI 2021 | Phase III study of NUC-1031 for first-line treatment of CCA

Rachna T. Shroff, MD, University of Arizona Cancer Center, Tucson, AZ, provides an update on NuTide:121, an ongoing Phase III study of NUC-1031, a nucleoside analog, and cisplatin vs gemcitabine and cisplatin for first-line treatment of patients with advanced cholangiocarcinoma (CCA). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter